Raymond James & Associates Has $1.03 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Raymond James & Associates Has $1.03 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Raymond James & Associates grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) by 34.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,331 shares of the company's stock after acquiring an additional 4,717 shares during the period. Raymond James & Associates' holdings in Intellia Therapeutics were worth $1,026,000 as of its most recent SEC filing.
Raymond James&Associates在最近提交给美国证券交易委员会的13F文件中显示，第三季度，该公司持有的英特利亚治疗公司(纳斯达克：NTLA-GET评级)股票增加了34.6%。该公司持有18,331股该公司股票，在此期间又收购了4,717股。截至最近提交的美国证券交易委员会申请文件，Raymond James&Associates持有的Intellia治疗公司股份价值1,026,000美元。
A number of other large investors have also recently bought and sold shares of NTLA. National Bank of Canada FI acquired a new stake in Intellia Therapeutics during the 3rd quarter worth about $39,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Intellia Therapeutics by 462.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 866 shares of the company's stock valued at $48,000 after buying an additional 712 shares during the period. Penserra Capital Management LLC acquired a new stake in shares of Intellia Therapeutics in the 1st quarter valued at about $97,000. High Net Worth Advisory Group LLC grew its stake in shares of Intellia Therapeutics by 33.3% in the 3rd quarter. High Net Worth Advisory Group LLC now owns 2,000 shares of the company's stock valued at $112,000 after buying an additional 500 shares during the period. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of Intellia Therapeutics by 10.2% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company's stock valued at $123,000 after buying an additional 220 shares during the period. 85.61% of the stock is currently owned by institutional investors and hedge funds.
其他一些大型投资者最近也买卖了NTLA的股票。加拿大国民银行FI在第三季度收购了Intellia Treeutics的新股份，价值约3.9万美元。中国环球资产管理有限公司在第三季度增持了英特利亚治疗公司的股份462.3%。中国环球资产管理有限公司目前持有该公司866股股票，价值48,000美元，在此期间又购买了712股。Penserra Capital Management LLC在第一季度收购了Intellia治疗公司的新股份，价值约97,000美元。第三季度，高净值咨询集团在Intellia Treeutics的股份增加了33.3%。高净值咨询集团现在拥有该公司2000股股票，价值11.2万美元，在此期间又购买了500股。最后，Steward Partners Investment Consulting LLC在第二季度将其在Intellia Treeutics的股份增加了10.2%。Steward Partners Investment Consulting LLC现在拥有2368股该公司的股票，价值12.3万美元，在此期间又购买了220股。85.61%的股票目前由机构投资者和对冲基金持有。
Insider Buying and Selling
内幕买卖
In related news, EVP Laura Sepp-Lorenzino sold 2,508 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $93,322.68. Following the sale, the executive vice president now owns 19,959 shares of the company's stock, valued at approximately $742,674.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Laura Sepp-Lorenzino sold 2,508 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $93,322.68. Following the completion of the transaction, the executive vice president now directly owns 19,959 shares in the company, valued at approximately $742,674.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Glenn Goddard sold 2,427 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total transaction of $90,308.67. Following the completion of the transaction, the chief financial officer now owns 15,404 shares of the company's stock, valued at $573,182.84. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,608 shares of company stock valued at $431,934. 3.90% of the stock is owned by company insiders.
在相关新闻中，执行副总裁Laura Sepp-Lorenzino在1月4日星期三的一笔交易中出售了2,508股Intellia治疗公司的股票。这些股票的平均价格为37.21美元，总价值为93,322.68美元。出售后，执行副总裁总裁现在持有该公司19959股股票，价值约742,674.39美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可在美国证券交易委员会网站。在相关新闻中，执行副总裁Laura Sepp-Lorenzino在1月4日星期三的一笔交易中出售了2,508股Intellia治疗公司的股票。这些股票的平均价格为37.21美元，总价值为93,322.68美元。交易完成后，执行副总裁总裁现在直接持有该公司19,959股股份，价值约742,674.39美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过以下方式获取这个环节。此外，首席财务官格伦·戈达德在1月4日星期三的一笔交易中出售了2,427股Intellia治疗公司的股票。这些股票的平均价格为37.21美元，总成交金额为90,308.67美元。交易完成后，首席财务官现在拥有15,404股公司股票，价值573,182.84美元。关于这次销售的披露可以找到这里。在上个季度，内部人士出售了11,608股公司股票，价值431,934美元。3.90%的股份由公司内部人士持有。
Analyst Ratings Changes
分析师评级发生变化
Intellia Therapeutics Trading Up 7.8 %
Intellia治疗公司股价上涨7.8%
NASDAQ:NTLA opened at $41.63 on Friday. The stock has a market capitalization of $3.28 billion, a PE ratio of -7.09 and a beta of 1.93. The firm's 50 day moving average is $39.40 and its 200 day moving average is $51.99. Intellia Therapeutics, Inc. has a 12 month low of $32.44 and a 12 month high of $104.87.
纳斯达克：NTLA上周五开盘报41.63美元。该股市值为32.8亿美元，市盈率为-7.09，贝塔系数为1.93。该公司的50日移动均线切入位为39.40美元，200日移动均线切入位为51.99美元。Intellia Treateutics，Inc.的12个月低点为32.44美元，12个月高位为104.87美元。
Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($1.31) by ($0.18). The company had revenue of $13.27 million during the quarter, compared to the consensus estimate of $13.60 million. Intellia Therapeutics had a negative return on equity of 47.79% and a negative net margin of 859.92%. Research analysts predict that Intellia Therapeutics, Inc. will post -6.09 earnings per share for the current year.
Intellia治疗公司(纳斯达克代码：NTLA-GET评级)最近一次公布季度收益结果是在11月3日星期四。该公司公布了该季度每股收益(1.49美元)，低于分析师普遍预期的(1.31美元)和(0.18美元)。该公司本季度的收入为1327万美元，而市场普遍预期为1360万美元。Intellia治疗公司的净资产回报率为负47.79%，净利润率为负859.92%。研究分析师预测，Intellia治疗公司本年度每股收益将达到6.09美元。
About Intellia Therapeutics
关于Intellia Treateutics
(Get Rating)
(获取评级)
Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
Intellia Treateutics，Inc.是一家临床阶段的基因组编辑公司，致力于使用CRISPR/Cas9系统开发治疗疗法。它的CRISPR/Cas9系统通过生产只需一个疗程就能永久编辑和/或纠正人体内疾病相关基因的疗法来改变医学，并创造出可以治疗肿瘤和免疫疾病的工程细胞。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Intellia Therapeutics (NTLA)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免费获取StockNews.com关于Intellia治疗(NTLA)的研究报告
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升，提振销售观点
- KLA公司：在动荡不安的半市场中站稳脚跟
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating).
想看看其他对冲基金持有NTLA吗？访问HoldingsChannel.com获取Intellia治疗公司(纳斯达克代码：NTLA-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Intellia治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Intellia治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。